Chemotherapy in the treatment and control of leishmaniasis (Q36492721)

14 August 2017

1 reference

title

Chemotherapy in the treatment and control of leishmaniasis (English)

1 reference

14 August 2017

1 reference

3

Piero Olliaro

1 reference

14 August 2017

Jorge Alvar

1

1 reference

PubMed ID

16735166

14 August 2017

Simon Croft

series ordinal

2

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

Advances in Parasitology

1 reference

14 August 2017

61

1 reference

14 August 2017

223-274

1 reference

Profile of kala-azar in north India.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis: consequences to women in a Bangladeshi community

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

1 reference

7 January 2021

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The leishmaniases as emerging and reemerging zoonoses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Estimation of population at risk of infection and number of cases of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

rK39: A Cloned Antigen of Leishmania chagasi that Predicts Active Visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

HIV viral load and response to antileishmanial chemotherapy in co-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Comparison of active and passive case detection of cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Chemotherapy of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmaniasis. Public health aspects and control

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The increase in risk factors for leishmaniasis worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmania/HIV co-infections: epidemiology in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Associations of Phlebotomus orientalis and other sandflies with vegetation types in the eastern Sudan focus of kala-azar.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A comparison of the direct agglutination test and enzyme-linked immunosorbent assay in the sero-diagnosis of leishmaniasis in the Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Epidemiology of visceral leishmaniasis in northeast Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis treatment, Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmania major and HIV co-infection in Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Reciprocal relationships between undernutrition and the parasitic disease visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

1 reference

7 January 2021

Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis and HIV in Tigray, Ethiopia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Development and characterization of paromomycin-resistant Leishmania donovani promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of recurrent cutaneous Leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of visceral leishmaniasis in 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The sensitivity of Leishmania species to aminosidine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Embryotoxicity of meglumine antimoniate in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis associated with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmania/HIV co-infection in Brazil: an appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Sodium stibogluconate cardiotoxicity and safety of generics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

[American cutaneous leishmaniasis associated with HIV/AIDS: report of four clinical cases]

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Antigenuria in visceral leishmaniasis: detection and partial characterisation of a carbohydrate antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Visceral Leishmaniasis and HIV Coinfection in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Miltefosine for new world cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The de novo selection of drug-resistant malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The world's most neglected diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

An overview of paediatric leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

Subclinical form of the American visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-308X%2805%2961006-8

7 January 2021

10.1016/S0065-308X(05)61006-8

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16735166